Clinical Trials Browser

Interventional × enasidenib × 90 days × Clear all

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

NCT05564390 2026-04-17

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Phase 2 Recruiting

2,000 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06672146 2026-04-17

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

93 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06176989 2026-04-08

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Phase 2 Recruiting

40 enrolled

CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT06756308 2026-04-07

A Study of Enasidenib in People With T-Cell Lymphoma

Phase 2 Recruiting

25 enrolled

Lymphoid

Lymphoma, T-Cell

NCT05756777 2026-03-27

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Phase 1 Recruiting

18 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03728335 2026-03-13

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Phase 2 Recruiting

35 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Phase 2 Recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Phase 1/2 Active not recruiting

130 enrolled 38 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03383575 2026-02-17

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Phase 2 Recruiting

63 enrolled

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05102370 2026-01-27

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Phase 1 Completed

4 enrolled

Classical hematology

Clonal Cytopenia of Undetermined Significance

Clinical Trials

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

A Study of Enasidenib in People With T-Cell Lymphoma

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance